Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. VEGF-C as a putative therapeutic target in cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Application of cell-free DNA for genomic tumor profiling: a feasibility study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Getting the Most from Your High-Dimensional Cytometry Data

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The anatomy of single cell mass cytometry data

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Analysis of Mass Cytometry Data

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Anders Handrup Kverneland
  • Magnus Pedersen
  • Marie Christine Wulff Westergaard
  • Morten Nielsen
  • Troels Holz Borch
  • Lars Rønn Olsen
  • Gitte Aasbjerg
  • Saskia J Santegoets
  • Sjoerd H van der Burg
  • Katy Milne
  • Brad H Nelson
  • Özcan Met
  • Marco Donia
  • Inge Marie Svane
Vis graf over relationer

Immune therapy is a promising field within oncology but has been unsuccessful in ovarian cancer (OC). Still, there is rationale and evidence supporting immune therapy in OC. We investigated the potential for adoptive cell therapy (ACT) from in vitro expanded tumor-infiltrating lymphocytes (TILs) in combination with checkpoint inhibitors (ICI) and conducted immunological testing of ex vivo expanded TILs (REP-TILs). Six patients with late-stage metastatic high-grade serous OC were treated with immune therapy consisting of ipilimumab followed by surgery to obtain TILs and infusion of REP-TILs, low-dose IL-2 and nivolumab. One patient achieved a partial response and 5 others experienced disease stabilization for up to 12 months. Analysis of the REP-TILs with flow- and mass-cytometry show primarily activated and differentiated effector memory T cells. REP-TILs showed in vitro reactivity and expression of inhibitory receptors, such as LAG-3 and PD-1. Furthermore, our data indicate that addition of ipilimumab therapy improves the T cell fold expansion during production, increase the level of CD8 T cell tumor reactivity, and favorably affect the T cell phenotype. We show that the combination of ICI and ACT is feasible and safe. With one partial response and one long-lasting SD, we demonstrated the potential of ACT in OC.

OriginalsprogEngelsk
TidsskriftOncotarget
Vol/bind11
Udgave nummer22
Sider (fra-til)2092-2105
Antal sider14
ISSN1949-2553
DOI
StatusUdgivet - 2 jun. 2020

Bibliografisk note

Copyright: © 2020 Kverneland et al.

ID: 61244004